A Multicenter, Randomized, Double-Blind, Phase II Study to Evaluate the Safety, Tolerance and Efficacy of Multiple Doses of SCH 56592 Versus Fluconazole in the Treatment of Oropharyngeal Candidiasis (OPC) in HIV-Positive Patients

CompletadoFase 2ClinicalTrials.gov

ID: NCT00002399Tipo: INTERVENTIONAL

Traducción no disponible, mostrando original

Resumen

The purpose of this study is to compare the safety and effectiveness of SCH 56592 with that of fluconazole in the treatment of OPC (a fungal infection of the throat) in HIV-positive patients.

Descripción detallada

This is a randomized, multicenter, double-blind study consisting of 5 arms (4 dose levels of SCH 56592 vs fluconazole) in the treatment of oropharyngeal candidiasis (OPC) in HIV-positive patients.

Elegibilidad

Edad mínima: 18 YearsEdad máxima: 65 YearsSexo: ALL

Criterios de inclusión

Patients must have:
Documented HIV seropositivity (by Western blot or other approved confirmatory test) prior to enrollment.
Pseudomembranous oropharyngeal candidiasis.
Fungal stain or KOH consistent with Candida species, confirmed by a positive mycologic culture.
Ability to swallow study medication.

Criterios de exclusión

Co-existing Condition:
Patients with any of the following symptoms and conditions are excluded:
Medical condition requiring use of prohibited drugs.
Primary HIV seroconversion-related mucosal candidiasis.
Systemic candidiasis.
All forms of OPC other than pseudomembranous (unless accompanied by pseudomembranous OPC).
Documented or suspected fungal esophagitis in patients with symptoms of esophagitis.
EKG with prolonged QTc interval or clinically-significant abnormalities.
Concurrent Medication:
Excluded:
Systemic antifungals (IV or oral).
Topical oral antifungals, e.g., Nystatin, Mycelex, etc.
Medications known to interact with azoles and that may lead to life-threatening side effects:
terfenadine, astemizole, cisapride, ebastine, triazolam, midazolam.
Medications known to lower the serum concentration/efficacy of azole antifungals:
rifampin, carbamazepine, phenytoin, rifabutin, barbiturates, isoniazid, H2 blockers.
Cytokines (except erythropoietin), interferon, or lymphocyte replacement therapy unless patient already taking these agents for at least 30 days prior to enrollment.
Protease inhibitors, starting for the first time, 30 days prior to study enrollment.
Cytotoxic therapy for cancer.
Oral or intravenous corticosteroids at supraphysiologic doses (prednisone 10 mg/day or greater; hydrocortisone 40 mg/day or greater; dexamethasone 2 mg/day or greater.
Patients with any of the following prior conditions are excluded:
Prior enrollment in this study.
Less than 3 months life expectancy.
History of hypersensitivity to azole antifungals.
History of failed therapy with fluconazole 100 mg/day for 2 weeks in the last 3 months.
Prior Medication:
Excluded (wash-outs for medications):
Systemic antifungals (IV, oral) within 14 days prior to enrollment.
Topical oral antifungals within 1 day prior to enrollment.
Oral or intravenous corticosteroids at supraphysiologic doses within 10 days prior to enrollment.
Astemizole within 10 days prior to enrollment.
Drugs known to lower the serum concentration/efficacy of azole antifungals within 30 days prior to enrollment.
Investigational drug (unlicensed new chemical entity) use within 30 days prior to enrollment.
Current known drug abuse, in the opinion of the lead investigator, that would interfere with the subject's participation in the study.

Intervenciones

drug

Posaconazole

drug

Fluconazole

Ubicaciones

Centro de Micologia / Facultad de Medicina UBA

Buenos Aires, Argentina

Hosp Fernandez

Buenos Aires, Argentina

Patrocinadores

PrincipalSchering-Plough

Aviso: La información de este ensayo proviene de fuentes públicas y tiene carácter exclusivamente informativo. No constituye asesoramiento médico, regulatorio ni de ningún otro tipo. Las traducciones son automatizadas y no poseen validez oficial. Consultá siempre con un profesional de la salud. Ver Términos de Uso.

A Multicenter, Randomized, Double-Blind, Phase II Study t... | EligiMed